We are thrilled to announce that Allied Biotech Corp. (1780.TW), a leading global manufacturer of carotenoid ingredients, is scheduled to go public on the Taipei Exchange (TPEx) this June, with a tentative underwriting price of NT$20 per share.

With over 20 years of dedication,Allied Biotech Corp. has emerged as a powerhouse in the global carotenoid market, standing alongside industry giants DSM and BASF as one of the global players shaping international standards.

📈 Key Highlights:
Robust Financial Growth: Achieved double-digit growth in the first four months of 2026, with cumulative revenue reaching NT$343 million (a 14.62% YoY increase).

Dual-Engine Technical Barriers: Mastering both complex synthesis and advanced formulation technologies, Allied Biotech Corp. delivers crystalline lycopene with a purity level exceeding 95%—significantly outperforming the industry average of 70%.

Global Footprint: Our proprietary brands—Altratene, Lycotene, and Lutein—are distributed across over 60 countries, successfully penetrating the supply chains of the world's top food and beverage giants and top flavor & fragrance leaders.

The "Clean Label" Megatrend: As the US FDA moves to phase out 6 major artificial colorants by the end of 2026 under the "Make America Healthy Again" initiative, Allied Biotech Corp.’s comprehensive spectrum of natural carotenoids is poised to be the ultimate substitution solution. Major US food brands are already conducting sample testing.

"We don’t just supply ingredients; we help define global standards," says Chairman Cheng-Li Yang. As a proud participant in international regulatory formulation alongside the UN and the EU, Altratene is ready to fuel the next wave of clean-label transformation worldwide.

Stay tuned as we embark on this exciting new chapter on the public market!